An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Inclusion Criteria:
The study population eligible for this study is adult male or female patients of good
performance status having a histologically confirmed recurrent or metastatic SCCHN, not
amenable to standard curative or palliative therapies.
- Diagnosis of squamous cell carcinoma of the oral cavity, nasal cavity, paranasal
sinuses, nasopharynx, oropharynx, hypopharynx or larynx.
- Primary or recurrent disease for which no curative or established palliative
treatments are amenable
- WHO performance status of 1 or 2.
Exclusion Criteria:
- Received certain other treatments within 4 weeks prior to administration of study
drug
- Previous severe allergic reactions (e.g. angio-edema, severe asthma, or anaphylaxis).
- Skin disease requiring systemic or local corticosteroid therapy.
- Known brain metastasis or leptomeningeal disease.
- Signs or symptoms of acute illness.
- Bacterial, fungal or viral infection.
- Certain serious medical conditions, including kidney or liver disease, some
psychiatric illnesses, myocardial infarction within one year and stomach, lung,
heart, hormonal, nerve or blood diseases.
- Pregnant or breast-feeding women.
- Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth
control during the whole trial.
- Simultaneous participation in any other trial involving investigational drugs or
having participated in a trial within 4 weeks prior to start of trial treatment.